Shots:
- Abbott has received European CE Mark approval for the Esprit BTK Everolimus Eluting Resorbable Scaffold System to treat people with peripheral artery disease (PAD) below the knee (BTK)
- Esprit was evaluated in the LIFE-BTK trial against balloon angioplasty in pts (n >260) with PAD BTK, which showed sustained efficacy & ability to open vessels & reducing reclosures, with 48% fewer repeat procedures over the study period. Data was highlighted at VIVA’24
- The Esprit BTK System is a resorbable scaffold that is implanted via a minimally invasive catheter procedure to support below-the-knee vessels after blockage clearance, then gradually dissolves as the vessel heals
Ref: Abbott | Image: Abbott | Press Release
Related News:- Abbott Secures European CE Mark for Volt PFA System to Treat Atrial Fibrillation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
